1. |
NHLBI/WHO workshop report: Gobal strategy for the Diagnosis, Management, and Prevention of Chronic obstructive Pulmonary Disease. 2006.
|
2. |
CELI B R, MACNEE W. Standards for the diagnosis and treatment of patients with COPD: asummayy of the ATS/ERS position paper[J]. Eur Respir J, 2004,23:932946.
|
3. |
National Heart, Lung, and Blood Institute. Global initrative for chronic obstructive pulmonary disease. NHLBI Workshop Repot 2701,22001, Apr. Chapter 4.
|
4. |
FABBN L M, DURHAM S, HOLGATE S T, et al. Niewoehneral. Assessment of airway inflammation: an overview[J]. Eur Respir J Suppl, 1998,26:6s8s..
|
5. |
MALTAIS F, OSTINELLI J, BOURBEAU J, et al. Comparison of nebulized acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial[J]. Am J Respir Care Med,2002,165:698703.
|
6. |
韩伟,周新.布地奈德雾化治疗在COPD急性加重期的应用[J].实用临床医药杂志,2004,8:68.
|
7. |
NIEWOEHNER D E, ERBLAND M L, DEUPREE R H, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease[J]. N Engl J Med,1999,340:19411947.
|
8. |
SONG I H, BUTTGEREIT F. Nongenomic glucocorticoid effects to provde the basis for new drug develooments[J]. Mol Cell Endocrinol,2006,246(12):1426.
|
9. |
MENDES E S, PEREIRA A, DANTA I, et al. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids[J]. Eur Respir J, 2003,21 (6):98993.
|
10. |
MIRICI A, MERAL M, AKGUN M. Comparison of the Efficacy of Nebulised Budesonide with Parenteral Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease[J]. Clin Drug Invest, 2003,23 (1):5562.
|
11. |
OUDIJK E J, LAMMERS J W, KOENDERMAN L. Systemic inflammation in chronic obstructive pulmonary disease[J]. Eur Respir J,2003,46:S5S13.
|